MTIP
ALXN

Magee Thomson Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Magee Thomson Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-40,670
Closed -$4.75M – 105
2016
Q2 		$4.75M Sell
40,670
-4,540
-10% -$644K 1.66% 26
2016
Q1 		$6.29M Sell
45,210
-920
-2% -$135K 1.99% 27
2015
Q4 		$8.8M Buy
46,130
+540
+1% +$94.3K 2.42% 25
2015
Q3 		$7.13M Sell
45,590
-32,760
-42% -$5.98M 2.2% 25
2015
Q2 		$14.2M Sell
78,350
-8,810
-10% -$1.52M 4.11% 4
2015
Q1 		$15.1M Sell
87,160
-2,100
-2% -$380K 3.65% 13
2014
Q4 		$16.5M Buy
89,260
+11,990
+16% +$2.22M 4.11% 7
2014
Q3 		$12.8M Sell
77,270
-52,950
-41% -$8.7M 3.16% 13
2014
Q2 		$20.3M Sell
130,220
-10,580
-8% -$1.67M 4.97% 2
2014
Q1 		$21.4M Sell
140,800
-1,468
-1% -$233K 4.86% 3
2013
Q4 		$18.9M Sell
142,268
-32,050
-18% -$3.85M 4.18% 4
2013
Q3 		$20.2M Sell
174,318
-3,500
-2% -$384K 4.07% 6
2013
Q2 		$16.4M Buy
+177,818
New +$17.1M 3.73% 8

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Magee Thomson Investment Partners's ALXN Position: Q3 2016 in Review

Magee Thomson Investment Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 40,670 shares — an estimated $4.75M sold.

Magee Thomson Investment Partners first reported a position in ALXN in Q2 2013 and held it in 13 quarters. The position peaked at $21.4M in Q1 2014. 517 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • Magee Thomson Investment Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 40,670 Alexion Pharmaceuticals shares in Q3 2016, an estimated $4.75M.
  • Magee Thomson Investment Partners first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Magee Thomson Investment Partners's Alexion Pharmaceuticals position peaked at $21.4M in Q1 2014.
  • 517 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Magee Thomson Investment Partners's 13F filing for Q3 2016, filed 27 Oct 2016.